Detection of K-ras Gene Mutations in Peripheral Blood Free DNA in Patients with Non-Small Cell Lung Cancer_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

GaoHang , YinJun ,  BaoYong

Department of Respiratory Medicine, The Third People's Hospital of Chengdu, Chengdu, Sichuan, 610031, China;

Corresponding?author：

BaoYong, Email: byong65@163.com

Keywords：

Non-small cell lung cancer; Peripheral blood; K-ras gene mutation

DOI：

10.7507/1671-6205.2016107

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the clinical significancy of K-ras gene mutation in peripheral blood free DNA in patients with non-small cell lung cancer (NSCLC). Methods A total of 242 patients pathologically diagnosed with NSCLC in the Third People's Hospital of Chengdu were recruited between January 2013 and August 2015. Both tumor tissues and peripheral blood free DNA were collected for detection of K-ras gene mutation by mutant-enriched liquidchip technology. The detection rate was compared between these two kinds of samples. Results In tumor tissues, the K-ras gene mutation was detected in 12 cases with a positive rate of 4.96%. While in peripheral blood samples, the K-ras gene mutation was detected in 10 cases with a positive rate of 4.13%. The detection yield of K-ras gene mutation in peripheral blood had a good consistency with that of lung cancer tissues (Kappa value=0.81). Conclusion K-ras in peripheral blood plasma free DNA can be a surrogate marker for tumor tissues' K-ras gene mutation in screening patients with NSCLC.

Citation： Gao Hang, Yin Jun, Bao Yong. Detection of K-ras Gene Mutations in Peripheral Blood Free DNA in Patients with Non-Small Cell Lung Cancer. Chinese Journal of Respiratory and Critical Care Medicine, 2016, 15(5): 458-460. doi: 10.7507/1671-6205.2016107 Copy

1.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CACancer J Clin, 2016, 66:115-132.
2.	Paez JG, Janne PA, Lee JC, et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.Science, 2004, 304:1497-1500.
3.	Lynch TJ, Bell DW, Scrdella R, et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib.N Engl J Med, 2004, 350:2129-2139.
4.	楊帆, 陳克終, 劉宏偉, 等.K-ras突變導致肺癌細胞對表皮生長因子受體抑制劑耐藥的機制.中華試驗外科雜志, 2011, 28:1232-1233.
5.	Han SW, Kim TY, Jeon YK, et al.Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.Clin Cancer Res, 2006, 12:2538-2544.
6.	Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.Clin Cancer Res, 2007, 13:2890-2896.
7.	Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer:a meta-analysis of 22 studies. Lung Cancer, 2010, 69:272-278.
8.	Marks JL, Broderock S, Zhou Q, et al.Prognostic and therapeutic implications of EGFR and KRAS mutations in respected lung adenocarcinoma.J Thorac Oncol, 2008, 3:111-116.
9.	Wu CC, Hsu HY, Liu HP, et al.Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.Cancer, 2008, 113:3199-3208.
10.	張海萍, 付莉, 陳培瓊, 等.特異引物雙擴增即時PCR與傳統測序法檢測腸癌、肺癌患者K-ras基因突變的比較.中華病理學雜志, 2010, 39:757-761.
11.	羅煒, 王慧, 徐韞健, 等.非小細胞肺癌患者KRAS基因突變情況分析.廣東醫學, 2014, 35:2025-2028.
12.	張卉, 楊新杰, 秦娜, 等.肺腺癌EGFR與KRAS基因突變狀態分析.中國肺癌雜志, 2015, 18:686-690.
13.	張卉, 楊新杰, 秦娜, 等.肺鱗癌EGFR與KRAS基因突變狀態分析.中國肺癌雜志, 2015, 18:621-625.
14.	衣素琴, 莊園, 朱衛東, 等.非小細胞肺癌中KRAS基因突變分析.中華臨床醫師雜志(電子版), 2013, 7:9111-9115.
15.	許春偉, 張立英, 吳永芳, 等.非小細胞肺癌患者外周血與組織中K-ras基因突變的研究.貴州醫藥, 2015, 39:1-3.
16.	Wu S, Zhu Z, He J, et al.A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples.Clin Chem Lab Med, 2010, 48:1103-1106.

1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CACancer J Clin, 2016, 66:115-132.
2. Paez JG, Janne PA, Lee JC, et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.Science, 2004, 304:1497-1500.
3. Lynch TJ, Bell DW, Scrdella R, et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib.N Engl J Med, 2004, 350:2129-2139.
4. 楊帆, 陳克終, 劉宏偉, 等.K-ras突變導致肺癌細胞對表皮生長因子受體抑制劑耐藥的機制.中華試驗外科雜志, 2011, 28:1232-1233.
5. Han SW, Kim TY, Jeon YK, et al.Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.Clin Cancer Res, 2006, 12:2538-2544.
6. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.Clin Cancer Res, 2007, 13:2890-2896.
7. Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer:a meta-analysis of 22 studies. Lung Cancer, 2010, 69:272-278.
8. Marks JL, Broderock S, Zhou Q, et al.Prognostic and therapeutic implications of EGFR and KRAS mutations in respected lung adenocarcinoma.J Thorac Oncol, 2008, 3:111-116.
9. Wu CC, Hsu HY, Liu HP, et al.Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.Cancer, 2008, 113:3199-3208.
10. 張海萍, 付莉, 陳培瓊, 等.特異引物雙擴增即時PCR與傳統測序法檢測腸癌、肺癌患者K-ras基因突變的比較.中華病理學雜志, 2010, 39:757-761.
11. 羅煒, 王慧, 徐韞健, 等.非小細胞肺癌患者KRAS基因突變情況分析.廣東醫學, 2014, 35:2025-2028.
12. 張卉, 楊新杰, 秦娜, 等.肺腺癌EGFR與KRAS基因突變狀態分析.中國肺癌雜志, 2015, 18:686-690.
13. 張卉, 楊新杰, 秦娜, 等.肺鱗癌EGFR與KRAS基因突變狀態分析.中國肺癌雜志, 2015, 18:621-625.
14. 衣素琴, 莊園, 朱衛東, 等.非小細胞肺癌中KRAS基因突變分析.中華臨床醫師雜志(電子版), 2013, 7:9111-9115.
15. 許春偉, 張立英, 吳永芳, 等.非小細胞肺癌患者外周血與組織中K-ras基因突變的研究.貴州醫藥, 2015, 39:1-3.
16. Wu S, Zhu Z, He J, et al.A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples.Clin Chem Lab Med, 2010, 48:1103-1106.

Chinese Journal of Respiratory and Critical Care Medicine

Detection of K-ras Gene Mutations in Peripheral Blood Free DNA in Patients with Non-Small Cell Lung Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content